Journal of the National Comprehensive Cancer Network
Beyond the Guidelines in the Treatment of Peripheral T-cell Lymphoma: New Drug Development CME

Disclosures

Release Date: April 30, 2008; Valid for credit through April 30, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

    Beyond the Guidelines in the Treatment of Peripheral T-cell Lymphoma: New Drug Development
    Andy I. Chen, MD, PhD
    Ranjana H. Advani, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the most common types of peripheral T-cell lymphomas (PTCLs) in North America
  2. Describe the 5-year disease-free survival rate for PTCLs
  3. Identify chemotherapy regimens currently used for the treatment of PTCLs
  4. Describe overall response rates associated with the use of immunotherapies for the treatment of PTCLs
  5. Describe response rates of PTCLs to different antimetabolites
Authors and Disclosures

Andy I. Chen, MD, PhD
Disclosure: Andy I. Chen, MD, PhD, has disclosed no relevant financial relationships.


Ranjana H. Advani, MD
Disclosure: Ranjana H. Advani, MD, has disclosed that he has received clinical trial support from CuraGen Corporation and Ligand Pharmaceuticals, Inc.


Désirée Lie, MD, MSEd
Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.


Kerrin G. Robinson, MA
Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.